Janux Therapeutics, Inc. (JANX) SEC Filings & Earnings Calls

Clinical-stage company with no approved products; net loss; reliance on pipeline success.

“Net loss of $22M; no revenue; cash runway but no commercialization.”

No product revenue, history of losses

“The Company has incurred net losses and negative cash flows from operations since inception and had an accumulated deficit of $397.7 million as of June 30, 2026.” · word for word

Dependence on collaboration revenue

“For the three and six months ended June 30, 2026, all of the Company’s revenue related to a single customer.” · word for word

No product revenue and reliance on external financing

“The Company has incurred net losses and negative cash flows from operations since inception and had an accumulated deficit of $375.7 million as of March 31, 2026.” · word for word

Single customer concentration for revenue

“For the three months ended March 31, 2026, all of the Company’s revenue related to a single customer.” · word for word

Clinical development risk for pipeline candidates, especially JANX007 and JANX014.

“JANX007 still in Phase 1b; JANX014 just initiated; JANX008 discontinued.”

Dependence on BMS collaboration for milestone revenue; any change could impact cash flow.

“BMS milestone payment of $35M is a significant near-term cash inflow.”

Early-stage pipeline; no approved products

“We are early in our development efforts and all of our product candidates and research programs other than JANX007 and JANX008 are in the preclinical development or discovery stage.” · word for word

History of net losses; may never be profitable

“We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future.” · word for word

Novel technology unproven in late-stage trials

“Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.” · word for word

Pre-revenue biotech with increasing net loss and R&D spend; no approved products or revenue stream.

“Net loss increased to $113.6M in FY2025 from $69.0M in FY2024; R&D expenses rose to $125.9M.”

Dependence on clinical trial success for pipeline candidates JANX007, JANX008, JANX011.

“Pipeline candidates are in early clinical stages; Phase 1 data for JANX007 and JANX008 expected in 2026.”

Development risk: collaboration depends on successful preclinical and clinical development; Janux has limited control over BMS's efforts.

“Janux will complete preclinical development up to IND submission. Bristol Myers Squibb will hold the IND and be responsible for subsequent development and global commercialization” · word for word

Milestone uncertainty: total potential milestones of $800M are contingent on development, regulatory, and commercial success, which may not materialize.

“eligible to receive development, regulatory and commercial milestones up to approximately $800 million in the aggregate” · word for word

Clinical-stage biotech with no approved products or product revenue

“The Company has incurred net losses and negative cash flows from operations since inception and had an accumulated deficit of $319.4 million as of September 30, 2025.” · word for word

Dependence on collaboration revenue from single customer

“For the three and nine months ended September 30, 2025 and 2024, all of the Company's revenue related to a single customer.” · word for word

Clinical-stage company with no approved products or revenue; depends on trial success and financing.

“Clinical-stage biopharmaceutical company; no revenue reported; net loss of $24.3M; R&D spend increasing.”